National Cancer Institute awards $1.9M grant to PLx Pharma — 4 insights

The Bethesda, Md.-based National Cancer Institute awarded PLx Pharma a $1.9 million grant to support the drugmakers' aspirin for chemoprevention to treat colorectal cancer.

Here's what you should know.

1. The grant will help the drugmaker continuing refining the aspirin.

2. Lenard M. Lichtenberger, PhD, of Houston-based University of Texas Health Science Center, will serve as principal investigator.

3. The principle study will examine the aspirin's role in colorectal cancer prevention.

4. The grant will come in two annual installments in 2017 and 2018.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast